Introduction {#s1}
============

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by its irreversible, alternating episodes and impaired joint function (Popescu et al., [@B32]). Patients with RA often suffered from the arthralgia caused by the synovial lining joints swelling which can result in disability and reduction of life quality (Donahue et al., [@B12]). Generally, patients with RA often have a shorter life expectancy compared with normal people. Thus, the primary treating target of RA patients is to maximize the quality of life associated with health through preventing structural damage, controlling the symptom of inflammation, normalizing functional, and social participation (Smolen et al., [@B38]; Buckley et al., [@B7]). Until now, there are an estimated 1.12% of adult people affected with RA in developed countries (Li et al., [@B26]; Stevenson et al., [@B42]) which leads us to find optional treatments for patients with this disease.

Recently, the potent pro-inflammatory cytokine named tumor necrosis factor-α (TNF-α) has been considered playing an important role in immune responses and inflammationincluding those involved in RA (Brennan et al., [@B6]), Which indicated that TNF antagonists could be an effective method for RA treatments (Lee and Bae, [@B25]). However, based on the American College of Rheumatology (ACR) recommendations for the treatment of RA, it should begin with the use of conventional (non-biologic) disease-modifying antirheumatic drugs (cDMARDs), mostly are methotrexate (MTX) (Singh et al., [@B36]). If patients were tolerant of cDMARDs or showed inadequate responses (IR), biologic agents were often applied with cDMARDs as combined therapies. On the other hand, because of cDMARDs\' side effects including hepatotoxicity, primary gastrointestinal symptoms and respiratory symptoms, around one-third RA patients are treated with monotherapy of biologic agents (Listing et al., [@B27]; Heiberg et al., [@B20]; Soliman et al., [@B39]). Up to now, a total of five kind of biologic agents have been approved to treat patients with RA: (Popescu et al., [@B32]) TNF antagonists, known as anti-TNF agents (aTNF) including infliximab (IFX), certolizumab (CZP), adalimumab (ADA), golimumab (GOL), and etanercept (ETN); (Donahue et al., [@B12]) monoclonal antibody which could suppress B cells such as rituximab; (Buckley et al., [@B7]) monoclonal antibody which could suppress interleukin-6 (IL-6) receptor such as tocilizumab (TCZ); (Smolen et al., [@B38]) selective T-cell costimulatory modulator such as abatacept; (Stevenson et al., [@B42]) interleukin-1 (IL-1) receptor antagonists such as anakinra (Buckley et al., [@B7]).

However, no randomized controlled trial (RCT) has been conducted to evaluate all optional biologic treatments simultaneously. Clinicians now were facing increasing challenge about choosing optimal drug due to the amount of alternative biologic treatments and other DMARDs. Thus, network meta-analysis (NMA) has been applied, which could combine all the available RCTs and evaluate the potential biologic drugs through not only direct but also indirect comparison. In recent years, several NMAs of biologic treatments for patients with RA have been published (Buckley et al., [@B7]; Lee and Bae, [@B25]; Migliore et al., [@B28]; Stevenson et al., [@B42]; Choi et al., [@B10]). Nevertheless, those studies only focused on combined treatments such as biologic therapies with MTX. Particularly, none of the existing NMA contained all optional biologic agents. Besides, none of the existing NMA distinguished between cDMARD-naive and cDMARD-experienced. According to Egsmose et al., Tsaknoas et al., and Quinn et al., there is a period named "window of opportunity" and the underlying process of inflammatory in RA was more susceptible to biologic drugs than later time-points (Egsmose et al., [@B14]; Tsakonas et al., [@B43]; Quinn et al., [@B33]). In the early period of RA, the mechanical aspects and pathogenic of autoimmune prompted inflammation was not fully consistent with the current evidence of RA (Mullan and Bresnihan, [@B29]). Correspondingly, the RCTs on patients with RA who are cDMARD-naive should be picked out from the pool.

In this study, a comprehensive NMA was conducted to evaluate the relative efficacy and safety of 11 potential therapeutic approaches of early interventions for patients with RA. The outcomes of efficacy would be evaluated through remission and ACR scores. ACR scores that measuring changes in symptoms of RA and different degrees of improvement are referred to ACR20, ACR50, and ACR70. For example, ACR20 measures a 20% improvement on a scale of 28 intervals. As for safety, the outcomes would consist of the incidence of adverse effects (AEs) and serious adverse effects (SAEs). The purpose of this current research is to supplement the existing evidence network and select the optimal treatments for patients with RA.

Methods {#s2}
=======

Selection strategy
------------------

We did a comprehensive research to find all relevant RCTs through Embase, PubMed, Cochrane Library and ClinicalTrials.gov with the following keywords: "rheumatoid arthritis," "methotrexate," "infliximab," "etanercept," "adalimumab," "golimuma," "tocilizumab," and "randomized control trial," etc. There is no limitation on the time of publication. All the searching process was limited to clinical trials, and no age or language restrictions were applied to literature search. Process of screening was carried out through reading titles and abstracts of eligible articles. After that, full texts of remaining articles were further read to remove articles with incomplete or irrelevant information.

Inclusion and exclusion criteria
--------------------------------

All the included articles must satisfy the following criteria: (i) studies should be randomized and all involved RA patients were adults who had not treat with cDMARDs before trials; (ii) trials must include at least two of the concerning treatments for RA; (iii) trials should contain at least one of the primary outcomes of interest (as shown below). Moreover, expert opinions, editorials, letters, case reviews, reports and duplications would be excluded after title and abstract screening.

Data extraction and quality assessment
--------------------------------------

All the relevant data would be extracted from the eligible studies by two independent reviewers using a standard data collection form. Any discrepancies between reviewers would be resolved by discussing with a third independent researcher. In this study, the following information would be collected: (i) baseline information including first author, publication date, sample size, blinding method, type of intervention, following time, disease durations, gender, and age; (ii) efficacy outcomes including ACR20, ACR50, ACR70, and remission; (iii) safety outcomes including AEs and SAEs.

Statistical analysis
--------------------

On the foundation of a rigorous assessment of the accuracy and authenticity of the collected data, we introduced a Bayesian framework utilizing Software R 3.2.3 and STATA 13.0 for statistical processing. One of the most significant properties of NMA is to combine all the available comparisons including the indirect evidence simultaneously. In this NMA research, the forest plots showed the results of each outcome. For binary variables (ACR20, ACR50, ACR70, remission, AEs, SAEs), odds ratios (ORs) with their 95% credible intervals (CrI) were applied for the comparison. Furthermore, relative ranking probability of each therapeutic method was calculated through surface under cumulative ranking curve (SUCRA), which is also an advantage of the Bayesian framework. Typically, a more satisfying treatment assessed under a certain outcome was indicated by a higher SUCRA value. As for the consistency analysis, the consistency between direct and indirect evidence of each outcome were conducted through node-splitting analysis and heat plots. Besides, random effects model would be implemented if significant inconsistency was found (*P*-value \< 0.05).

Results {#s3}
=======

Study selection and characteristics of included studies
-------------------------------------------------------

We identified 2,527 published articles according to the searching strategy which has been mentioned before. Then 864 articles were removed for duplicated, and after scanning title and abstract 1,427 articles were also removed for lack of relevance. 216 studies were eventually excluded. At the end, a total of 20 studies published from 2000 to 2016 met our selection criteria and has been involved in this NMA (Bathon et al., [@B2]; Nishimoto et al., [@B31]; St Clair et al., [@B41]; Quinn et al., [@B34]; Breedveld et al., [@B5]; Durez et al., [@B13]; Bejarano et al., [@B3]; Emery et al., [@B16],[@B18], [@B17], [@B15]; Goekoop-Ruiterman et al., [@B19]; Soubrier et al., [@B40]; van Vollenhoven et al., [@B44]; Burmester et al., [@B8]; Detert et al., [@B11]; Kavanaugh et al., [@B23]; Hørslev-Petersen et al., [@B21]; Atsumi et al., [@B1]; Bijlsma et al., [@B4]), among which 12 were two-arm trials, 6 were three-arm trials and 2 were four-arm trials. The baseline characteristics of included studies were presented in Table [1](#T1){ref-type="table"}. Overall, 9,047 patients with RA were contained and the average age of them was 52.4 ± 10 years. The network structures of ACR scores, remission and safety were shown in Figure [1](#F1){ref-type="fig"} and in the diagram, each circle represents an individual treatment and the thickness of lines represents the number of trials.

###### 

Patient characteristics in the studies included in the analysis.

  **Study, first author, year**                  **Blinding**    **Follow up (weeks)**   **Sizes**   **Outcomes**   **Intervention**   **Cases**   **Female**   **Disease durations (year)**   **Age (year)**
  ---------------------------------------------- --------------- ----------------------- ----------- -------------- ------------------ ----------- ------------ ------------------------------ ----------------
  Swefot (TBD), van Vollenhoven et al., [@B44]   Open-label      52                      258         ①③④            cDMARDs            130         101          0.525 (0.3)                    53.9 (13.9)
                                                                                                                    IFX+MTX            128         97           0.517 (0.29)                   51.1 (13.3)
  Nishimoto, 2004, Nishimoto et al., [@B31]      Double-blind    12                      162         ①③             PBO                53          39           8.4                            53
                                                                                                                    TCZ                54          40           7.3                            53.5
                                                                                                                    TCZ                55          46           8.3                            56
  GUEPARD, Soubrier et al., [@B40]               Unblinded       52                      65          ①②             cDMARDs            32          26           4.4                            49.3 (15.2)
                                                                                                                    ADA+MTX            33          26           4.4                            46.3 (16.3)
  ASPIRE, St Clair et al., [@B41]                Not specified   46                      1,004       ①②③④           cDMARDs            282         212          0.9 (0.7)                      50 (13)
                                                                                                                    IFX+MTX            359         255          0.8 (0.7)                      51 (12)
                                                                                                                    IFX+MTX            363         247          0.9 (0.8)                      50 (130)
  OPTIMA, Kavanaugh et al., [@B23]               Double-blind    26                      1,032       ①②③④           ADA+MTX            515         380          0.33 (0.3)                     50.7 (14.5)
                                                                                                                    cDMARDs            517         382          0.375 (0.6)                    50.4 (13.6)
  BeST, Goekoop-Ruiterman et al., [@B19]         Double-blind    26                      254         ①③④            cDMARDs            126         86           0.44                           54 (13)
                                                                                                                    IFX+MTX            128         85           0.62                           54 (14)
  GO-BEFORE, Emery et al., [@B17]                Double-blind    24                      637         ①②③④           cDMARDs            160         134          2.9 (4.80)                     48.6 (12.91)
                                                                                                                    GOL                159         134          4.1 (5.60)                     48.2 (12.85)
                                                                                                                    GOL+MTX            159         135          3.5 (5.65)                     50.9 (11.32)
                                                                                                                    GOL+MTX            159         125          3.6 (6.09)                     50.2 (11.87)
  COMET, Emery et al., [@B16]                    Double-blind    104                     528         ①②③④           cDMARDs            263         191          0.78 (0.03)                    52.3 (0.8)
                                                                                                                    ETN+MTX            265         196          0.73 (0.03)                    50.5 (0.9)
  Durez2007, Durez et al., [@B13]                Double-blind    52                      29          ①              cDMARDs            14          10           0.45 (0.29)                    53.8 (15.2)
                                                                                                                    IFX+MTX            15          5            0.36 (0.31)                    50.0 (9.9)
  PREMIER, Breedveld et al., [@B5]               Double-blind    104                     799         ①②             ADA+MTX            268         193          0.7 (0.8)                      51.9 (14.0)
                                                                                                                    ADA                274         212          0.7 (0.8)                      52.1 (13.5)
                                                                                                                    cDMARDs            257         190          0.8 (0.9)                      52.0 (13.1)
  Bathon, 2000, Bathon et al., [@B2]             Double-blind    52                      632         ①③             cDMARDs            217         163          1 (0.92)                       49 (13)
                                                                                                                    ETN                208         156          0.92 (0.83)                    50 (13)
                                                                                                                    ETN                207         153          1 (0.92)                       51 (13)
  Bejarano, 2008, Bejarano et al., [@B3]         Double-blind    56                      128         ①②③④           cDMARDs            73          39           0.66 (0.45)                    47 (9)
                                                                                                                    ADA+MTX            75          44           0.79 (0.5)                     47 (9)
  HITHARD, Detert et al., [@B11]                 Double-blind    48                      172         ①②④            ADA+MTX            87          61           0.15 (0.17)                    47.2 (12.12)
                                                                                                                    cDMARDs            85          57           0.13 (0.14)                    52.5 (14.34)
  Quinn, 2005, Quinn et al., [@B34]              Double-blind    52                      20          ①②             IFX+MTX            10          N/A          0.62 (0.38)                    51.3 (9.5)
                                                                                                                    cDMARDs            10          N/A          0.5 (0.31)                     53.1 (13.7)
  OPERA, Hørslev-Petersen et al., [@B21]         Double-blind    52                      180         ①④             ADA+MTX            89          56           88 days                        56.2
                                                                                                                    cDMARDs            91          63           83 days                        54.2
  C-EARLY, Emery et al., [@B15]                  Double-blind    52                      868         ①②③④           cDMARDs            213         170          0.24 (0.24)                    51.2 (13.0)
                                                                                                                    CZP+MTX            655         497          0.24 (0.38)                    50.4 (13.6)
  U-Act-Early, Bijlsma et al., [@B4]             Double-blind    24                      317         ①③④            TCZ+MTX            106         65           24.5 days                      53
                                                                                                                    TCZ                103         78           25.5 days                      55
                                                                                                                    cDMARDs            108         69           27.0 days                      53.5
  Function, Burmester et al., [@B8]              Double-blind    52                      1,157       ①②③④           cDMARDs            287         229          0.4 (0.48)                     49.6 (13.1)
                                                                                                                    TCZ+MTX            288         228          0.4 (0.49)                     51.2 (13.84)
                                                                                                                    TCZ+MTX            290         228          0.5 (0.53)                     49.5 (13.70)
                                                                                                                    TCZ                292         219          0.5 (0.48)                     49.9 (13.22)
  C-OPERA, Atsumi et al., [@B1]                  Double-blind    24                      316         ②③④            cDMARDs            157         127          N/A                            49 (10.3)
                                                                                                                    CZP+MTX            159         129          N/A                            49.4 (10.6)
  RADIATE, Emery et al., [@B18]                  Double-blind    24                      489         ①②③④           TCZ+MTX            170         84           12.6 (9.3)                     53.9 (12.7)
                                                                                                                    TCZ+MTX            161         81           11.0 (8.5)                     50.9 (12.5)
                                                                                                                    cDMARDs            158         79           11.4 (9.2)                     53.4 (13.3)

*① ACR*.

*② Remission*.

*③ adverse effects (AEs)*.

*④ serious adverse effects*.

*cDMARDs: conventional disease-modifying antirheumatic drugs; MTX: methotrexate; ADA: adalimumab; CZP: certolizumab; ETN: etanercept; GOL: golimumab; IFX: infliximab; TCZ: PBO: tocilizumab; placebo*.

![Full network of comparisons of efficacy and safety outcomes (The width of the lines is proportional to the number of trials comparing each pair of treatments; the area of circles represents the cumulative number of patients for each intervention).](fphar-09-00138-g0001){#F1}

Network meta-analysis
---------------------

ACR20, ACR50, ACR70, and remission were used to estimate the effectiveness of each therapeutic method and the results were shown in Figure [2](#F2){ref-type="fig"}. According to the results of ACR scores, TCZ+MTX, IFX+MTX, and ETN+MTX showed statistical difference compared with cDMARDs alone on ACR20, ACR50, and ACR70, which indicated the superior efficacy of these drug combinations. Apart from that, as for remission, CZP+MTX (OR = 5.20, 95% CrI: 1.20--21.0), TCZ (OR = 3.20, 95% CrI: 1.10--10.0), TCZ+MTX (OR = 4.20, 95% CrI: 1.80--12.0) were statistically significant compared to cDMARDs. Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} showed the results of safety outcomes on AEs and SAEs, and according to that, there is no significant difference of the concerning treatments compared with cDMARDs and PBO.

![The Odds ratio estimate with 95% credible intervals of efficacy endpoints compared to DMARDs.](fphar-09-00138-g0002){#F2}

###### 

The odds ratio estimate with 95% credible intervals of AEs for each pair-wise comparison.

  ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------- ------------------- -------------------- ------------------- --------------------
  **ADA+MTX**         0.84 (0.38, 1.8)    1.20 (0.41, 3.56)   0.40 (0.10, 1.51)   0.79 (0.20, 3.16)   0.66 (0.21, 2.03)   1.17 (0.37, 3.63)    1.09 (0.39, 2.86)   0.97 (0.19, 4.26)    0.91 (0.29, 2.39)   1.40 (0.52, 3.74)
  1.19 (0.55, 2.61)   **cDMARDs**         1.42 (0.68, 3.06)   0.47 (0.16, 1.42)   0.95 (0.30, 2.97)   0.78 (0.34, 1.84)   1.40 (0.60, 3.19)    1.30 (0.69, 2.34)   1.15 (0.28, 4.10)    1.08 (0.49, 2.05)   1.67 (0.90, 3.06)
  0.84 (0.28, 2.46)   0.70 (0.33, 1.48)   **CZP+MTX**         0.33 (0.09, 1.26)   0.66 (0.17, 2.59)   0.55 (0.18, 1.70)   0.98 (0.31, 2.94)    0.91 (0.34, 2.34)   0.81 (0.16, 3.53)    0.76 (0.25, 1.99)   1.16 (0.44, 3.06)
  2.51 (0.66, 9.78)   2.12 (0.70, 6.30)   3.00 (0.79, 11.7)   **ETN**             2.01 (0.41, 9.78)   1.65 (0.42, 6.49)   2.97 (0.75, 11.82)   2.75 (0.76, 9.49)   2.44 (0.40, 13.07)   2.29 (0.58, 8.00)   3.53 (1.00, 12.43)
  1.26 (0.32, 5.05)   1.05 (0.34, 3.32)   1.51 (0.39, 5.93)   0.50 (0.1, 2.41)    **ETN+MTX**         0.83 (0.20, 3.39)   1.48 (0.36, 6.05)    1.38 (0.37, 4.90)   1.22 (0.20, 6.62)    1.14 (0.28, 4.10)   1.75 (0.49, 6.49)
  1.52 (0.49, 4.85)   1.28 (0.54, 2.97)   1.82 (0.59, 5.70)   0.61 (0.15, 2.39)   1.21 (0.30, 5.00)   **GOL**             1.79 (0.78, 4.10)    1.67 (0.57, 4.57)   1.48 (0.28, 6.69)    1.39 (0.43, 3.82)   2.12 (0.76, 5.99)
  0.85 (0.28, 2.72)   0.71 (0.31, 1.67)   1.02 (0.34, 3.19)   0.34 (0.08, 1.34)   0.68 (0.17, 2.80)   0.56 (0.24, 1.28)   **GOL+MTX**          0.93 (0.32, 2.59)   0.83 (0.16, 3.78)    0.78 (0.24, 2.16)   1.19 (0.43, 3.39)
  0.91 (0.35, 2.56)   0.77 (0.43, 1.45)   1.09 (0.43, 2.97)   0.36 (0.11, 1.31)   0.73 (0.20, 2.72)   0.60 (0.22, 1.77)   1.07 (0.39, 3.10)    **IFX+MTX**         0.89 (0.19, 3.67)    0.84 (0.31, 2.01)   1.27 (0.55, 3.13)
  1.03 (0.23, 5.26)   0.87 (0.24, 3.6)    1.23 (0.28, 6.30)   0.41 (0.08, 2.51)   0.82 (0.15, 5.10)   0.68 (0.15, 3.53)   1.21 (0.26, 6.36)    1.13 (0.27, 5.21)   **PBO**              0.93 (0.30, 2.92)   1.43 (0.41, 5.99)
  1.09 (0.42, 3.46)   0.92 (0.49, 2.03)   1.31 (0.50, 4.06)   0.44 (0.12, 1.73)   0.88 (0.24, 3.56)   0.72 (0.26, 2.34)   1.28 (0.46, 4.18)    1.20 (0.50, 3.22)   1.07 (0.34, 3.32)    **TCZ**             1.52 (0.82, 3.39)
  0.71 (0.27, 1.93)   0.60 (0.33, 1.11)   0.86 (0.33, 2.27)   0.28 (0.08, 1.00)   0.57 (0.15, 2.05)   0.47 (0.17, 1.31)   0.84 (0.3, 2.34)     0.79 (0.32, 1.8)    0.70 (0.17, 2.46)    0.66 (0.30, 1.22)   **TCZ+MTX**
  ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------- ------------------- -------------------- ------------------- --------------------

*cDMARDs, conventional disease-modifying antirheumatic drugs; MTX, methotrexate; ADA, adalimumab; CZP, certolizumab; ETN, etanercept; GOL, golimumab; IFX, infliximab; TCZ, tocilizumab; PBO, placebo*.

###### 

The odds ratio estimate with 95% credible intervals of SAEs for each pair-wise comparison.

  ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  **ADA+MTX**         1.00 (0.64, 1.55)   1.05 (0.52, 2.16)   0.96 (0.40, 2.27)   0.42 (0.15, 1.19)   0.92 (0.36, 2.29)   1.16 (0.55, 2.32)   1.13 (0.59, 2.18)   1.11 (0.61, 2.01)
  1.00 (0.64, 1.55)   **cDMARDs**         1.05 (0.60, 1.86)   0.95 (0.45, 2.01)   0.42 (0.16, 1.07)   0.91 (0.41, 2.05)   1.16 (0.63, 1.99)   1.12 (0.71, 1.80)   1.11 (0.73, 1.65)
  0.95 (0.46, 1.93)   0.95 (0.54, 1.67)   **CZP+MTX**         0.90 (0.35, 2.27)   0.40 (0.13, 1.20)   0.87 (0.33, 2.32)   1.09 (0.48, 2.36)   1.06 (0.52, 2.23)   1.04 (0.52, 2.10)
  1.04 (0.44, 2.48)   1.05 (0.50, 2.20)   1.11 (0.44, 2.83)   **ETN+MTX**         0.44 (0.13, 1.43)   0.96 (0.32, 2.83)   1.23 (0.46, 3.03)   1.19 (0.50, 2.86)   1.16 (0.49, 2.69)
  2.36 (0.84, 6.82)   2.36 (0.93, 6.17)   2.51 (0.84, 7.61)   2.25 (0.70, 7.61)   **GOL**             2.16 (0.90, 5.64)   2.75 (0.92, 8.25)   2.66 (0.96, 7.61)   2.61 (0.94, 7.39)
  1.08 (0.44, 2.75)   1.09 (0.49, 2.46)   1.15 (0.43, 3.06)   1.04 (0.35, 3.10)   0.46 (0.18, 1.12)   **GOL+MTX**         1.27 (0.46, 3.35)   1.21 (0.48, 3.16)   1.20 (0.49, 2.97)
  0.86 (0.43, 1.80)   0.86 (0.50, 1.58)   0.91 (0.42, 2.10)   0.81 (0.33, 2.18)   0.36 (0.12, 1.08)   0.79 (0.30, 2.16)   **IFX+MTX**         0.96 (0.48, 2.12)   0.95 (0.49, 1.95)
  0.89 (0.46, 1.68)   0.90 (0.55, 1.40)   0.94 (0.45, 1.93)   0.84 (0.35, 1.99)   0.38 (0.13, 1.04)   0.83 (0.32, 2.08)   1.04 (0.47, 2.08)   **TCZ**             0.98 (0.61, 1.52)
  0.90 (0.50, 1.65)   0.90 (0.61, 1.36)   0.96 (0.48, 1.93)   0.86 (0.37, 2.03)   0.38 (0.14, 1.06)   0.84 (0.34, 2.03)   1.05 (0.51, 2.05)   1.02 (0.66, 1.63)   **TCZ+MTX**
  ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------

*cDMARDs, conventional disease-modifying antirheumatic drugs; MTX, methotrexate; ADA, adalimumab; CZP, certolizumab; ETN, etanercept; GOL, golimumab; IFX, infliximab; TCZ, tocilizumab; PBO, placebo*.

Ranking with SUCRA value
------------------------

Table [4](#T4){ref-type="table"} showed the results of ranking probabilities in terms of each outcome. As for the efficacy outcomes, TCZ+MTX ranked first on ACR50, ACR70 and ranked second on ACR20 and remission, which indicated its best performance among all treatments. With respect to alternative treatment options, ETN+MTX and IFX+MTX also performed well due to their higher SUCRA values compared with other treatments. And PBO ranked last on all efficacy outcomes as expected. Regarding the safety outcomes, though ETN ranked first followed by GOL for AEs and IFX+MTX, TCZ+MTX had the similar highest values for SAEs according to the SUCRA ranking, the conclusion about the relative safety of each concerning treatment seemed not so credible if we combined the results of forest plots. What\'s more, due to the lack of data, some SUCRA results were missing which may also reduce the reliability of the outcomes.

###### 

The SUCRA value of different treatments on each outcome.

            **ACR20**   **ACR50**   **ACR70**   **Remission**   **AE**   **SAE**
  --------- ----------- ----------- ----------- --------------- -------- ---------
  ADA       0.144       0.157       0.244       0.080                    
  ADA_MTX   0.603       0.576       0.624       0.347           0.449    0.449
  cDMARDs   0.290       0.274       0.277       0.130           0.613    0.437
  CZP_MTX   0.494       0.480       0.523       0.773           0.312    0.509
  ETN       0.198       0.146       0.186                       0.905    
  ETN_MTX   0.806       0.794       0.757       0.530           0.591    0.418
  GOL       0.351       0.355       0.227       0.299           0.742    0.039
  GOL_MTX   0.564       0.501       0.482       0.489           0.324    0.405
  IFX_MTX   0.717       0.721       0.714       0.568           0.373    0.603
  PBO       0.004       0.001       0.000                       0.473    
  TCZ       0.607       0.653       0.665       0.622           0.532    0.578
  TCZ_MTX   0.723       0.841       0.803       0.739           0.186    0.562

*cDMARDs, conventional disease-modifying antirheumatic drugs; MTX, methotrexate; ADA, adalimumab; CZP, certolizumab; ETN, etanercept; GOL, golimumab; IFX, infliximab; TCZ, tocilizumab; PBO, placebo*.

Consistency analysis
--------------------

Figures [S1](#SM1){ref-type="supplementary-material"}--[S6](#SM6){ref-type="supplementary-material"} showed the results of node-splitting analysis and their corresponding heat plots. All the *P*-value was larger than 0.05 which revealed that there was no statistical inconsistency between direct and indirect comparisons among all outcomes. The same results came from the heat plots, which also contributed to the reliability of this NMA.

Discussion {#s4}
==========

RA was a type of chronic inflammatory arthritis, which would have negative effects on patients\' living quality. Moreover it can lead to functional limitations and employment obstacle (Singh et al., [@B35]). Many kinds of medications have been introduced to cure RA, including conventional DMARDs (like MTX), biologics (like IFX, ETN, ADA, and PCZ), and other concerning medicines (Jansen et al., [@B22]). The mechanism of biologic agents is that they can target TNF-α, IL-1, IL-6, T cells, or B cells, and significantly inhibit the damage of joint. In our NMA, we collected data from 20 eligible trials of 9,047 patients with RA who were cDRAMDs-naïve. Eleven interventions along with PBO were compared simultaneously on both efficacy and safety.

Four outcomes concerning efficacy were measured, including ACR20, ACR50, ACR70, and remission. As was shown in this NMA, all of the 11 therapies worked notably better than PBO. Moreover, we can also find that the combination of biological agents with MTX might be superior to monotherapy of cDMARDs, particularly TCZ+MTX, which performed well in all four outcomes with respect to efficacy. In addition, the monotherapy of TCZ also ranked roundly well in all outcomes despite that it was inferior to combination of TCZ and MTX. The results above were consistent to former trials. For instance, a double-blind, 2-year study (Kremer et al., [@B24]) containing 1196 RA patients indicated that TCZ+MTX had better efficacy on helping patients slow down the joint damage and improving their body function than MTX alone. IL-6 is a pleiotropic cytokine that can regulate the immune response, hematopoiesis, inflammation, and bone metabolism through combining with IL-6 receptor. The constitutive overproduction of IL-6 is considered to play a pathological role in RA (Nishimoto et al., [@B30]). Correspondingly, TCZ is a humanized monoclonal antibody that can suppress the bindling of IL-6 to membrane expressed IL-6 soluble receptors, thus preventing the pro-inflammatory activities of IL-6 or IL-6 receptor signaling (Kremer et al., [@B24]), which might explain TCZ as an effective medication for RA.

Apart from that, ETN+MTX and IFX+MTX also performed pretty well as alternative treatment options. According to previous studies, TNF is a kind of soluble protein playing an important role in RA. It is believed that TNF can lead to continuous occurrence of inflammatory response and progressive destruction of cartilage and bone (Brennan et al., [@B6]). Both ETN and IFX are TNF antagonists, which can be specifically combined with TNF-α and then break the activity of it to achieve the goal of controlling inflammation and continuing to alleviate the symptom of RA (Emery et al., [@B16]; Lee and Bae, [@B25]).

What more, when comparing the combinations of cDMARDs and biological agents with monotherapy of biologic agents, according to the results, the combination therapies, showed the much higher efficacy than the corresponding biologic medicine alone. While as for the safety outcomes, the results didn\'t show the significant difference, which also indicated the superiority of combination therapies.

When choosing an appropriate treatment, not only the efficacy, but also the safety ought to be considered. When it came to safety, the results of AEs together with SAEs were measured in this NMA. Though ETN ranked first with respect to avoiding adverse events and those medications which performed well in the outcomes of efficacy did not rank well in safety according to the SUCRA ranking, the result could not be so responsible due to the outcomes of forest plots which indicated that there is no statistical difference between those combinations of drugs and cDRAMDs alone.

Moreover, the main adverse events of those therapies included rhinopharyngitis, respiratory tract disorder, pathology of skin and soft tissue, gastrointestinal side effects and so on (Campbell et al., [@B9]). A study conducted among 48,676 participants (Singh et al., [@B37]) concluded that biologics were connected with significantly higher rates of tuberculosis reactivation, serious infections, total AEs and withdrawals resulted by AEs, which is worthy noticing. Therefore, due to the potential adverse effects, the use of effective interventions still needs further evaluation.

However, there are inevitably some limitations in our research. Firstly, the sample size of some outcomes was relatively small and duration time was relatively short, thus we could not obtain sufficient evidence to get general results. Secondly, most of the RCTs included in our NMA compared medications with cDMARDs, as a consequence, some direct comparisons between other treatments could not been achieved and we could not get a further understanding in the inconsistency among these RCTs. For instance, we were not able to compare ETN+MTX and TCZ+MTX directly. Besides, there were some confounding factors while analyzing the outcomes, which may have some effects on study. For example, doses across treatments had not been accounted for in this analysis. In addition, the different stages of RA might also affect the result of study since patients in different stages appeared varied symptoms and responded differently to medications.

In summary, based on the studies we selected, our NMA provided a systematic evaluation on the efficacy and safety of therapies on rheumatoid arthritis. Our NMA concluded that TCZ+MTX was potentially the most preferable treatment for RA, with ETN+MTX and IFX+MTX as alternative treatment options. However, considering the adverse effects, it should be introduced with caution and more advanced studies should be carried out to find out the most appropriate way for treating RA.
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The results of consistency analysis by note-splitting plot and heat plot of ACR50.
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The results of consistency analysis by note-splitting plot and heat plot of ACR70.
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The results of consistency analysis by note-splitting plot and heat plot of remission.
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The results of consistency analysis by note-splitting plot and heat plot of adverse events.
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The results of consistency analysis by note-splitting plot and heat plot of serious adverse events.
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